Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner

 
• By Kevin Grogan
  
Charts
Merck KgAA has been putting its case to the investment community • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business